AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Tumor-derived ER chaperone grp170 reduces pulmonary metastatic disease.
2003 JUN 18 - (NewsRx.com & NewsRx.net) -- Immunization with tumor-derived endoplasmic reticulum chaperone grp170 elicited a tumor-specific CD8+ T-cell response and reduced pulmonary metastatic disease.
"Glucose-regulated protein (grp) 170 is a molecular chaperone localized in endoplasmic reticulum (ER), which has been demonstrated to interact with the peptides translocated by transporter associated with antigen presentation (TAP). In our study, we have evaluated the therapeutic efficacy of tumor-derived grp170 against the highly metastatic and poorly immunogenic murine melanoma B16F10," investigators in the United States report.
"Immunization of mice with grp 170 preparations from autologous tumor significantly delayed progression of the primary cancer and reduced established pulmonary metastases, which was associated with the prolonged survival of metastases-bearing mice," stated Xiang-Yang Wang and collaborators at Roswell Park Cancer Institute in Buffalo, New York. "However, grp 170 from normal liver or antigenically distinct tumor failed to exhibit therapeutic effect. In addition, tumor-derived grp 170 elicited a potent cytotoxic T-lymphocyte response specific for B16F10 tumor, which correlates with in vivo protective effects.
"Adoptive transfer of splenocytes obtained from B16F10-grp170-primed animals remarkably suppressed pulmonary metastases. Depletion of either CD4+ or CD8+ T cells in priming phase significantly abrogated the ...
- Dendreon anti-Her-2/neu Cancer Vaccine Shown to Eradicate Tumors and Prolong...
- Press release article from: Business Wire November 6, 2002 700+ words
...their anti-Her-2/neu cancer vaccine APC8024, currently being...in the current issue of the International Journal of Cancer. Results demonstrated...our therapeutic prostate cancer vaccine that recently produced promising...
- Dendreon anti-Her-2/neu cancer vaccine shown to eradicate tumours and prolong...
- News wire article from: Asia Africa Intelligence Wire November 6, 2002 700+ words
...demonstrated that a version of its anti-Her-2/neu cancer vaccine APC8024, currently being tested in patients with breast...The results are published in the current issue of the International Journal of Cancer. Results demonstrated that all tumour-bearing...
- Generex cancer vaccine enhances T cell stimulation.
- Newspaper article from: Pharma Marketletter August 6, 2007 700+ words
USA-based Generex Biotechnology says that new study data published in the July 16 on-line edition of the International Journal of Cancer demonstrate the anti-tumor activity of its novel Ii-Key/HER-2/neu immunotherapeutic vaccine...
- Lung Cancer Vaccine Data Encouraging.
- Newspaper article from: Cell Therapy News March 1, 2003 700+ words
...I/II clinical trial of GVAX lung cancer vaccine, a patient-specific vaccine made...following treatment with GVAX lung cancer vaccine. In addition, two patients continue...may be more responsive to GVAX lung cancer vaccine. Five additional patients were reported...
- Cancer Vaccine Research Is Coming To Fruition, With A Number Of Products Now In...
- Press release article from: Business Wire June 11, 2008 700+ words
...http://www.researchandmarkets.com/research/eb249c/cancer_vaccine_dev) has announced the addition of the "Cancer Vaccine Developments to 2013 + Cancer Vaccine Tracker" report to their offering. The launch of Sanofi Pasteur...
- Cell Genesys Reports Encouraging Update From Initial Clinical Trial of GVAX(R)...
- Press release article from: PR Newswire February 13, 2003 700+ words
...II clinical trial of GVAX(R) lung cancer vaccine, a patient-specific vaccine made...following treatment with GVAX(R) lung cancer vaccine. In addition, two patients continue...more responsive to GVAX(R) lung cancer vaccine. Five additional patients were reported...
- Cell Genesys Launches Expanded Phase 2 Trial of GVAX(R) Lung Cancer Vaccine.
- Press release article from: PR Newswire April 1, 2003 700+ words
...2 clinical trial of GVAX(R) lung cancer vaccine in patients with advanced-stage...expanded Phase 2 trials of GVAX(R) lung cancer vaccine planned for this year, was prompted...2 clinical trial of GVAX(R) lung cancer vaccine in advanced-stage patients who had...
- Cell Genesys reports encouraging update from initial clinical trial of GVAX...
- News wire article from: Asia Africa Intelligence Wire February 13, 2003 700+ words
...I/II clinical trial of GVAX lung cancer vaccine, a patient-specific vaccine made...following treatment with GVAX lung cancer vaccine. In addition, two patients continue...may be more responsive to GVAX lung cancer vaccine. Five additional patients were reported...
- Cell Genesys Updates Clinical Data from Phase I/II GVAX(R) Lung Cancer Vaccine...
- Press release article from: PR Newswire December 17, 2001 700+ words
...multicenter Phase I/II GVAX(R) lung cancer vaccine trial which demonstrated a complete...following treatment with GVAX(R) lung cancer vaccine -- two of which are ongoing at 11...cancer who received GVAX(R) lung cancer vaccine following surgery, currently remain...
- Cell Genesys Launches Phase I/II Clinical Trial of High Potency GVAX(R)...
- Press release article from: PR Newswire April 17, 2001 700+ words
...potency version of GVAX(R) prostate cancer vaccine following encouraging Phase II clinical...an evaluation of GVAX(R) prostate cancer vaccine in combination with chemotherapy...new high potency GVAX(R) prostate cancer vaccine is an important milestone for Cell...
Source: HighBeam Research, Tumor-derived ER chaperone grp170 reduces pulmonary metastatic...